Enzon Pharmaceuticals, Inc.
Period Ending Dec 31, 2013 Dec 31, 2012 Dec 31, 2011 Dec 31, 2010
Total Revenue 34,493 42,600 48,072 97,865
Cost of Revenue - - - -
Gross Profit 34,493 42,600 48,072 97,865
Operating Expenses
Research and Development 2,715 21,005 41,106 57,018
Sales, General and Admin. 8,843 14,475 17,396 27,396
Non-Recurring Items 4,776 11,086 6,025 14,026
Other - - - -
Operating Income 18,159 (3,966) (16,455) (575)
Income From Continuing Operations
Add'l Income/Expense Items 2,087 2,378 1,826 3,753
Earnings Before Interest and Tax 20,246 (1,588) (14,629) 3,178
Interest Expense 2,124 5,330 5,929 6,315
Earnings Before Tax 18,122 (6,918) (20,558) (3,137)
Income Tax (28) (4,135) 205 (337)
Minority Interest - - - -
Equity Earnings Unconsolidated Subsidiary - - - -
Net Income Cont. Operations 18,150 (2,783) (20,763) (2,800)
Non Recurring Events
Discontinued Operations - - - 180,043
Extraordinary Items - - - -
Effect of Accounting Changes - - - -
Other Items - - - -
Net Income 18,150 (2,783) (20,763) 177,243
Preferred Stock and Other Adjustments - - - -
Net Income Applicable to Common Shareholders 18,150 (2,783) (20,763) 177,243